Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson’s with depression - Takeaways - MDSpire

Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson’s with depression

  • By

  • Meichen Liu

  • Xueting Xie

  • Yudan Liu

  • Hongbo Feng

  • Xinyao Wang

  • Xuemei Du

  • Huimin Zhang

  • January 3, 2026

  • 0 min

Share

  • 1

    Depression in Parkinson's disease (DPD) significantly impacts quality of life and accelerates disease progression.

  • 2

    Neuroimaging biomarkers, such as 18F-FDG PET, can help identify brain glucose metabolism patterns in DPD and major depressive disorder (MDD).

  • 3

    The study enrolled 75 participants, including 30 with MDD, 25 with DPD, and 20 with Parkinson's disease without depression (PD-ND).

  • 4

    Distinct differences in brain metabolic patterns between DPD and MDD may serve as potential biomarkers for differential diagnosis.

  • 5

    The research aims to explore correlations between depressive symptoms and specific brain regions in both MDD and DPD groups.

Original Source(s)

Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson’s with depression

  • by Meichen Liu, Xueting Xie, Yudan Liu, Hongbo Feng, Xinyao Wang, Xuemei Du, Huimin Zhang

  • January 3, 2026

Related Content

Psychological distress among dialysis patients during the COVID-19 Omicron pandemic: risk and protective factors across hemodialysis and peritoneal dialysis

The Mental Health Gap Doctors Don’t Close

National survey data also suggested lower treatment rates among health care workers with either condition.

Metacognitive model of suicidality: a study of Iranian inpatients